{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:20:14Z","timestamp":1778642414137,"version":"3.51.4"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["DA046100"],"award-info":[{"award-number":["DA046100"]}]},{"name":"NIH","award":["AI122390"],"award-info":[{"award-number":["AI122390"]}]},{"name":"NIH","award":["AI120898"],"award-info":[{"award-number":["AI120898"]}]},{"name":"Vilcek\/Goldfarb Fellowship Endowment Fund","award":["DA046100"],"award-info":[{"award-number":["DA046100"]}]},{"name":"Vilcek\/Goldfarb Fellowship Endowment Fund","award":["AI122390"],"award-info":[{"award-number":["AI122390"]}]},{"name":"Vilcek\/Goldfarb Fellowship Endowment Fund","award":["AI120898"],"award-info":[{"award-number":["AI120898"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The recent emergence of the Omicron BA.1 and BA.2 variants with heavily mutated spike proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal antibody therapy for severe COVID-19. After two immunizations of individuals with no history of previous SARS-CoV-2 infection with BNT162b2 vaccine, neutralizing titer against BA.1 and BA.2 were 20-fold decreased compared to titers against the parental D614G virus. A third immunization boosted overall neutralizing titers by about 5-fold but titers against BA.1 and BA.2 remained about 10-fold below that of D614G. Both Omicron variants were highly resistant to several of the emergency use authorized therapeutic monoclonal antibodies. The variants were highly resistant to Regeneron REGN10933 and REGN10987 and Lilly LY-CoV555 and LY-CoV016 while Vir-7831 and the mixture of AstraZeneca monoclonal antibodies AZD8895 and AZD1061 were significantly decreased in neutralizing titer. Strikingly, a single monoclonal antibody LY-CoV1404 potently neutralized both Omicron variants.<\/jats:p>","DOI":"10.3390\/v14061334","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T22:54:52Z","timestamp":1655679292000},"page":"1334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies"],"prefix":"10.3390","volume":"14","author":[{"given":"Hao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8497-4942","authenticated-orcid":false,"given":"Belinda M.","family":"Dcosta","sequence":"additional","affiliation":[{"name":"Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel R.","family":"Landau","sequence":"additional","affiliation":[{"name":"Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-9954","authenticated-orcid":false,"given":"Takuya","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"ref_1","unstructured":"(2022, March 29). CDC, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/omicron-variant.html?s_cid=11734:omicron%20vaccine:sem.ga:p:RG:GM:gen:PTN:FY22."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","article-title":"Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant","volume":"603","author":"Suzuki","year":"2022","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.cell.2022.04.035","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike","volume":"185","author":"Yamasoba","year":"2022","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Uraki, R., Kiso, M., Iida, S., Imai, M., Takashita, E., Kuroda, M., Halfmann, P.J., Loeber, S., Maemura, T., and Yamayoshi, S. (2022). Characterization and antiviral susceptibility of SARS-CoV-2 Omicron\/BA.2. Nature.","DOI":"10.1038\/s41586-022-04856-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"ref_6","unstructured":"Diamond, M., Halfmann, P., Maemura, T., Iwatsuki-Horimoto, K., Iida, S., Kiso, M., Scheaffer, S., Darling, T., Joshi, A., and Loeber, S. (2021). The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res. Sq."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chom.2022.04.014","article-title":"Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2","volume":"30","author":"Evans","year":"2022","journal-title":"Cell Host Microb."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eabn8543","DOI":"10.1126\/scitranslmed.abn8543","article-title":"SARS-CoV-2 BA.1 variant is neutralized by vaccine booster\u2013elicited serum but evades most convalescent serum and therapeutic antibodies","volume":"14","author":"Lusvarghi","year":"2022","journal-title":"Sci. Trans. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103944","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41467-022-28544-w","article-title":"Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection","volume":"13","author":"Zou","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03720-y","article-title":"In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants","volume":"385","author":"Edara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"(2022, March 29). Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jmv.27558","article-title":"Mutational and phylogenetic analyses of the two lineages of the Omicron variant","volume":"94","author":"Majumdar","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"ref_21","unstructured":"(2022, January 24). FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron."},{"key":"ref_22","unstructured":"(2022, February 03). ClinicalTrials.gov, Phase III Double-Blind, Placebo-Controlled Study of AZD7442 for Pre-Exposure Prophylaxis of COVID-19 in Adult. (PROVENT), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04625725."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108528","DOI":"10.1016\/j.celrep.2020.108528","article-title":"An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2","volume":"33","author":"Tada","year":"2020","journal-title":"Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1038\/s41598-021-84913-3","article-title":"Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities","volume":"11","author":"Noval","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:34:39Z","timestamp":1760139279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["v14061334"],"URL":"https:\/\/doi.org\/10.3390\/v14061334","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.15.480166","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]}}}